Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL PK and Safety in Japanese and Chinese Healthy Subjects
NCT07464535Phase 1Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Tonmya in fibromyalgia (FM) and post-traumatic stress disorder (PTSD), sponsored by Tonix Pharmaceuticals. Primary endpoints: Area Under the curve from time zero to infinity at 72 days, Area under the concentration-time zero to the last measurable concentration at 72 days and 4 more. Started Mar 2022; status: completed.
02
Drugs
Tonmya
03
Conditions
fibromyalgia (FM)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07464535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464535.